<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">There was a wide variation of DENV infection prevalence between sub-regions in Africa. There was difference in the DENV infection IgG seroprevalence between regions for participants with fever, varying from 3.6% in Eastern Africa to 52.6% in Western Africa, 
 <italic>p</italic> &lt; 0.0001 (no data from Southern Africa; Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">6</xref>). There was a difference in the DENV infection IgG seroprevalence between regions in apparently healthy participants, varying from 8.0% in Southern Africa to 38.6% in Central Africa, 
 <italic>p</italic> &lt; 0.0001 (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">7</xref>). The IgM seroprevalence in febrile participants varied from 6.6% in Western Africa to 35.2% in Central Africa, 
 <italic>p</italic> &lt; 0.001 (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">8</xref>). Among apparently healthy participants, this prevalence varied from 0.1% in Central Africa to 5.0% in Eastern Africa, 
 <italic>p</italic> = 0.044 (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">9</xref>). For RNA prevalence in febrile participants, the prevalence varied from 5.3% in Eastern Africa to 12.2% in Central Africa, without significant difference, 
 <italic>p</italic> = 0.270 (Supplementary Fig. 
 <xref rid="MOESM1" ref-type="media">10</xref>). There were not enough studies to perform subgroup analysis for RNA prevalence among apparently healthy participants.
</p>
